The 2025 Testosterone Label Change, Explained: A Boxed Warning Dropped, a New One Added

In February 2025, the U.S. Food and Drug Administration made two class-wide changes to the labels of prescription testosterone products in the same action. It directed manufacturers to remove the boxed warning about a possible increased risk of heart attack and stroke, and it added a warning that testosterone can raise blood pressure. Both changes are documented in the FDA's safety communication on class-wide labeling changes for testosterone products. A label change is a legal update to what a drug's package insert says. It is not a recommendation to take the drug, an endorsement of any product, or a declaration that the drug is safe for everyone.

That distinction matters, because the headlines have mostly captured only half of what happened.

What the boxed warning was, and why it came off

A boxed warning is the strongest caution the FDA can place on a prescription label. For years, testosterone products carried one raising the possibility of increased cardiovascular events, a concern rooted in older observational data and some earlier trials.

The removal followed the TRAVERSE trial, published in the New England Journal of Medicine in 2023 (Lincoff and colleagues; registered as NCT03518034). TRAVERSE was a randomized, double-blind, placebo-controlled study of 5,246 men aged 45 to 80 who had symptoms of hypogonadism, two fasting testosterone readings below 300 ng/dL, and either existing cardiovascular disease or a high risk of it. Participants used a testosterone gel or a placebo gel. Over a mean follow-up of roughly 33 months, the rate of the primary cardiac endpoint (a composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke) was about 7.0 percent with testosterone and 7.3 percent with placebo. Testosterone met the trial's threshold for noninferiority, meaning it did not raise that combined risk relative to placebo in this population.

Two things about that result deserve emphasis. First, "noninferior" means "not worse on this specific outcome," not "protective" and not "beneficial for the heart." Second, the finding applies to the people TRAVERSE actually enrolled: middle-aged and older men with a documented deficiency, not the general adult male population and not people using testosterone for reasons outside the studied indication.

The warning that was added

The same 2025 action added a warning that testosterone can increase blood pressure. This came from separate postmarket studies the FDA had required, using ambulatory blood pressure monitoring, which tracks blood pressure across a full day rather than at a single office visit. Those studies confirmed a blood-pressure increase across the class. Products that had completed such monitoring received label language describing the observed increase; products that had not yet completed it received a new precautionary warning. Higher blood pressure is itself a cardiovascular risk factor, which is part of why the net picture is more nuanced than "the heart warning is gone."

What did not change

The FDA kept the label's Limitation of Use. In plain terms: testosterone products remain approved only for men with low testosterone tied to specific diagnosed medical conditions affecting the testes, pituitary, or brain. No testosterone product is approved for low testosterone due solely to aging. The 2025 changes did not expand who the drug is approved for, and they did not convert testosterone into a treatment for ordinary age-related decline, fatigue, low libido, athletic performance, or general vitality.

TRAVERSE also reported some secondary signals worth knowing about, including a higher rate of certain heart-rhythm disturbances such as atrial fibrillation in the testosterone group. A boxed warning coming off does not mean every safety question is settled; it means one specific, heavily litigated question about the primary cardiac composite was addressed by a large trial.

How to read a label change like this

It helps to separate three ideas that headlines tend to blur together. A safety signal is a hint of possible harm. A trial result either supports or fails to support that signal in a defined group of people. A label is the regulator's summary of what the accumulated evidence justifies saying. In this case, a large trial did not confirm the earlier cardiovascular signal in men with diagnosed hypogonadism, so the strongest form of that warning was removed. Separately, blood-pressure data were strong enough to add a new caution. Both moves reflect evidence, not enthusiasm, and neither speaks to whether any individual should start or stop the drug.

Politically framed coverage sometimes treats a label change as a verdict for or against a treatment. Mechanically, it is neither. It is the FDA updating the printed risk information to match the current evidence base, keeping the pieces the data support and dropping the piece a rigorous trial did not.

For readers, the practical takeaway is narrow and specific. If you have seen the news, the accurate version is that the cardiovascular boxed warning was removed on the strength of a trial in men with a diagnosed deficiency, a blood-pressure warning was added, and the approved uses did not widen. This article is educational and is not medical advice; whether testosterone therapy is appropriate for any particular person is an individual decision to work through with a qualified clinician who knows that person's full history.